An expedient assay for determination of gemcitabine and its metabolite in human plasma using isocratic ion-pair reversed-phase high-performance liquid chromatography

Therapeutic Drug Monitoring

Volumn 25, Issue 5, 2003, Pages 552-557

  Wang, Ling Zhi ^a,b   Goh, Boon Cher ^a,b   Lee, How Sung ^b   Noordhuis, Paul ^c   Peters, Godefridus J ^c  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c NONE

Author keywords

2 ,2 difluorodeoxyuridine; Gemcitabine; HPLC; Ion pair; Plasma

Indexed keywords

FLOXURIDINE; GEMCITABINE; LY 198791; LY 264368;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD SAMPLING; BONE MARROW SUPPRESSION; CORRELATION COEFFICIENT; DRUG DETERMINATION; DRUG ELIMINATION; DRUG MONITORING; DRUG TOXICITY; HUMAN; HUMAN CELL; ION PAIR CHROMATOGRAPHY; METABOLITE; PRIORITY JOURNAL; QUALITY CONTROL; QUANTITATIVE ASSAY; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SIDE EFFECT;

CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEOXYCYTIDINE; FLOXURIDINE; HUMANS; SENSITIVITY AND SPECIFICITY;

EID: 0141923077     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200310000-00003     Document Type: Article

References (12)

1. Barton-Burke M. Gemcitabine: A pharmacologic and clinical overview. Cancer Nurs. 1999;22:176-183.
2. Vanhaperen VWTR, Veerman G, Boven E, et al. Schedule dependence of sensitivity to 2′,2′-difluorodeoxycytidine(gemeitabine) in relation to accumulation and retention of its triphosphate in solid tumor-cell lines and solid tumors. Biochem Pharmacol. 1994;48: 1327-1339.
3. Abbruzzese JL, Grunewald R, Weeks EA, et al. A phase-I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol. 1991;9:491-498.
4. Grunewald R, Kantarjian H, Du M, et al. Gemcitabine in leukemia-A phase-I clinical, plasma, and cellular pharmacology study. J Clin Oncol. 1992;10:406-413.
5. Veerman G, vanHaperen VWTR, Vermorken JB, et al. Antitumor activity of prolonged as compared with bolus administration of 2′,2′ -difluorodeoxycytidine in vivo against murine colon tumors. Cancer Chemoth Pharmacol. 1996;38:335-342.
6. Edzes HT, Peters GJ, Noordhuis P, et al. Determination of the antimetabolite gemcitabine (2′,2′-difluoro-2′-deoxycytine) and of 2′2′-difluoro-2′-deoxyuridine by F-19 nuclear-magnetic-resonance spectroscopy. Anal Biochem. 1993;214:25-30.
7. Guo PG, Ma JG, Li SL, et al. Targeted delivery of a peripheral benzodiazepine receptor ligand-gemcitabine conjugate to brain tumors in a xenograft model. Cancer Chemother Pharmacol. 2001; 48:169-176.
8. Venook AP, Egorin MJ, Rosner GL, et al. Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and leukemia group B 9565. J Clin Oncol. 2000; 18:2780-2787.
9. Kroep JR, Giaccone G, Voorn DA, et al. Gemcitabine and paclitaxel: Pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. J Clin Oncol. 1999;17: 2190-2197.
10. Freeman KB, Anliker S, Hamilton M, et al. Validated assay for the determination of gemcitabine in human plasma and urine using high-performance chromatography with ultraviolet detection. J Chromatogr B. 1995;665:171-181.
11. Shah VP, Midha KK, Dighe S, et al. Analytical methods validation-bioavailability, bioequivalence, and pharmacokinetic studies. J Pharml Sci. 1992;81(3):309-312.
12. Jansen PJ, Akers MJ, Amos RM, et al. The degradation of the antitumor agent gemcitabine hydrochloride in an acidic aqueous solution at pH 3.2 and identification of degradation products. J Pharml Sci. 2000;89:885-891.